Alcon Inc (ALC)
85.57
+0.07
(+0.08%)
USD |
NYSE |
Nov 21, 16:00
85.53
-0.04
(-0.05%)
After-Hours: 20:00
Alcon Debt to Equity Ratio
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.2238 |
| March 31, 2024 | 0.2252 |
| December 31, 2023 | 0.2293 |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | 0.2357 |
| September 30, 2022 | 0.2002 |
| June 30, 2022 | 0.2031 |
| March 31, 2022 | 0.2071 |
| December 31, 2021 | 0.2115 |
| September 30, 2021 | 0.2152 |
| Date | Value |
|---|---|
| June 30, 2021 | 0.216 |
| March 31, 2021 | 0.2173 |
| December 31, 2020 | 0.2184 |
| September 30, 2020 | 0.2198 |
| June 30, 2020 | 0.2207 |
| March 31, 2020 | 0.1801 |
| December 31, 2019 | 0.1794 |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | 0.0021 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.1794
Minimum
Dec 2019
0.2357
Maximum
Dec 2022
0.2127
Average
0.2167
Median
Debt to Equity Ratio Benchmarks
| AC Immune SA | 0.00 |
| CRISPR Therapeutics AG | -- |
| Addex Therapeutics Ltd | 0.00 |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 0.00 |